Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesANGLE plc

ANGLE plc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
1.175 GBX -1.23 ( 51.04%)
Last update at 2025-11-26T08:00:00Z
VOLUME
4760294
Market Cap
31.53M

Momentum Score

…

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.00
Low
1.22
High
52 Week Price Range
9.07
Low
55.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
2.40
Dividend Yield
-
Revenue TTM
1.82M
Revenue Per Share
0.01
Gross Profit TTM
-0.16M
Debt / Equity
0.12
ROE
-69.68%
Net Debt
-26.89M
ROCE
-54.25%
Diluted EPS TTM
-0.09

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Income before tax -24.44M -17.36M -13.74M -7.73M -10.87M
Minority interest - - - - -0.01M
Net income -21.69M -15.01M -11.61M -6.25M -8.94M
Selling general administrative 0.56M 0.34M 0.37M 3.50M 0.24M
Gross profit 0.61M 0.71M 0.60M -0.01M 0.52M
Reconciled depreciation 2.84M 1.49M 1.00M - 1.07M
Ebit -24.21M -17.23M -13.73M -12.63M -10.90M
Ebitda -21.23M -15.72M -12.23M - -9.82M
Depreciation and amortization 2.97M 1.52M 1.50M - 1.07M
Operating income -24.21M -17.23M -13.73M -7.70M -10.90M
Other operating expenses 25.25M 18.25M 14.49M 1.55M 11.58M
Interest expense 0.37M 0.16M 0.09M 0.00M 0.02M
Tax provision -2.75M -2.35M -2.14M -1.48M -1.94M
Interest income 0.14M 0.03M 0.08M 0.02M 0.03M
Net interest income -0.23M -0.13M -0.01M - 0.03M
Income tax expense -2.75M -2.35M -2.14M -2.22M -1.94M
Total revenue 1.04M 1.01M 0.76M 0.58M 0.68M
Total operating expenses 24.82M 17.95M 14.33M - 11.42M
Cost of revenue 0.43M 0.30M 0.17M 0.59M 0.15M
Total other income expense net -0.23M -0.13M -0.01M - 0.03M
Net income from continuing ops -21.69M -15.01M -11.61M - -8.93M
Net income applicable to common shares -21.69M -15.01M -11.61M -11.33M -8.94M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Total assets 49.87M 47.31M 39.05M 34.30M 23.02M
Intangible assets 0.56M 1.37M 1.50M 5.49M 6.83M
Other current assets - 5.78M 3.57M - 2.84M
Total liab 9.80M 6.99M 4.71M 3.98M 3.68M
Total stockholder equity 40.06M 40.33M 34.34M 30.32M 19.34M
Deferred long term liab 0.03M 0.04M 0.12M 0.21M 3.00M
Other current liab 0.61M 1.04M 1.86M 0.32M 1.90M
Common stock 26.06M 23.51M 21.54M 17.28M 14.35M
Capital stock 26.06M 23.51M 21.54M - 14.35M
Retained earnings -103.70M -83.81M -69.14M -57.57M -51.64M
Other liab 0.22M 0.26M - - -
Good will 2.21M 2.21M 2.21M 2.21M 2.21M
Other assets 0.03M 0.04M 0.12M 0.21M 3.00M
Cash 31.90M 31.84M 12.08M 18.77M 11.01M
Total current liabilities 5.25M 4.91M 3.78M 2.78M 3.68M
Net debt -26.89M -29.50M -10.72M - -11.01M
Short term debt 0.66M 0.52M 0.43M - -
Short long term debt total 5.00M 2.34M 1.36M 1.55M -
Other stockholder equity 117.71M 100.62M 81.94M -0.38M 56.63M
Property plant equipment 8.48M 4.38M 2.41M 3.02M 1.35M
Total current assets 38.63M 39.37M 32.93M 23.58M 14.84M
Net tangible assets 37.33M 36.76M 30.75M 22.83M 15.51M
Short term investments - - 16.54M - -
Net receivables 1.80M 1.27M 2.99M 3.70M 2.38M
Inventory 2.06M 1.75M 0.74M 0.79M 0.99M
Accounts payable 3.98M 4.39M 3.34M 0.91M 3.68M
Accumulated other comprehensive income - - - - -1.47M
Common stock total equity - - 21.54M - 14.35M
Treasury stock - - -0.10M -0.10M -0.10M
Non currrent assets other - 3.57M - - 8.18M
Non current assets total 11.24M 7.95M 6.12M - 8.18M
Capital lease obligations 5.00M 2.34M 1.36M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2019-04-30
Investments -1.75M 14.77M -1.53M -22.51M -22.51M
Change to liabilities -0.98M 1.42M 0.87M -1.76M 0.61M
Total cashflows from investing activities -1.75M 14.77M -1.97M -23.35M -1.32M
Net borrowings -0.81M -0.61M -0.46M -0.35M -0.35M
Total cash from financing activities 18.10M 18.99M 18.14M 25.01M 12.00M
Change to operating activities 0.59M 0.59M 0.59M 0.59M -
Net income -24.44M -17.36M -13.74M -11.33M -10.87M
Change in cash 0.06M 19.76M 8.32M -10.88M 3.37M
Begin period cash flow 31.84M 12.08M 3.76M 11.01M 7.64M
End period cash flow 31.90M 31.84M 12.08M 3.76M 11.01M
Total cash from operating activities -16.05M -14.01M -7.85M -12.55M -7.31M
Issuance of capital stock 19.05M 19.69M 18.65M - 12.00M
Depreciation 2.84M 1.49M 1.42M 1.16M 1.07M
Other cashflows from investing activities 0.14M 0.02M 0.07M 0.06M 0.03M
Change to inventory -0.58M -1.01M 0.01M 0.14M -0.58M
Change to account receivables -0.65M 0.20M -0.66M 0.47M -0.09M
Sale purchase of stock - - 18.65M 16.92M 12.00M
Other cashflows from financing activities -0.95M -0.70M -0.51M -0.02M -1.32M
Change to netincome 5.20M -1.09M 2.17M -1.40M 0.67M
Capital expenditures 1.89M 1.79M 0.51M 0.79M 1.35M
Change in working capital -1.61M 0.61M 0.23M -0.51M -0.07M
Stock based compensation 4.39M 1.32M 0.27M - 0.33M
Other non cash items 2.78M 0.13M 0.01M - -0.03M
Free cash flow -17.94M -15.80M -8.35M - -8.67M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AGL
ANGLE plc		 -1.23
51.04%		 1.18 - - 18.87 0.88 5.81 -0.49
IDHC
Integrated Diagnostics Holdings PLC		 -
-%		 0.48 0.20 12.89 3.33 6.89 3.22 8.79
HVO
hVIVO plc		 -
-%		 5.55 7.05 18.32 0.89 1.01 0.69 2.93
ABDX
Abingdon Health Plc		 -
-%		 9.00 - 53.19 2.19 3.19 1.81 -0.25
CLBX
CelLBxHealth plc		 -
-%		 0.60 - - 7.05 1.50 6.07 -1.62

Profile*

ANGLE plc

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in Europe, North America, and the United Kingdom. The company develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in metastatic breast cancer patient blood; and HyCEAD. ANGLE plc has a partnership agreement with Bio View Ltd to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 1994 and is based in Guildford, the United Kingdom.

Surrey Research Park, Guildford, United Kingdom, GU2 7AF

44 14 8334 3434

https://angleplc.com

173

Name Title Year Born
Mr. Andrew David William Newland Founder, CEO & Exec. Director 1962
Mr. Ian Francis Griffiths CFO, Fin. Director, Company Sec. & Exec. Director 1965
Mr. Martin Cooke Director of Operations & Regulatory Affairs 1969
Mr. Andrew John Holder Head of Investor Relations 1968
Mr. Paul Smith Chief Commercial Officer NA
Dr. Madeline Repollet Head of Clinical Laboratories NA
Ms. Anne-Sophie Pailhes-Jimenez Head of R&D - ANGLE Europe Ltd. NA
Mr. Michael O'Brien Bus. Devel. Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…